Journal of Clinical Case Reports

The Efficacy of Pioglitazone Treatment in Myotonic Dystrophy Type 1 and Type 2 Diabetes Mellitus Patient

Abstract

Tohru Eguchi, Masumi Miyazaki and Shozo Miyauchi

Myotonic Dystrophy Type 1 (DM1) is the most common muscular dystrophy worldwide, with a prevalence of ranged from 1 in 8,300. The disease is an autosomal dominant neuromuscular disorder and characterized by muscle weakness, dystrophic changes in neuromuscular tissues, frontal baldness, cataracts, cardiac disorder and insulin resistance.